Search results
Showing 16 to 30 of 45 results for diabetic medicine
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Summary of the evidence on antimicrobial prescribing: delafloxacin
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.
with an interest in leukaemia research. Following graduation and general medicine experience in Manchester he trained in haematology,...
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.